Total pelvic exenterations in patients with locally advanced primary and recurrent rectal tumors: possibilities of urinary tract reconstruction

Surgical and long-term results of 14 total pelvic exenteration were analyzed. The group included 6 patients (5 men, 1 woman) with primary rectal cancer, and 8 patients (7 men, 1 woman) with the locally-advanced recurrent rectal cancer. The mean operative time was 403 ± 133.1 min (from 240 to 680 min). The average blood loss — 5169 ml (1200 to 15 000 ml). Both female patients were underwent infralevatoric total pelvic exenteration. Supralevatoric total pelvic exenteration were performed in 5 male patients. In these patients full recovery of the colon passage, and in the urinary tract — orthotopic plastic of the urinary bladder (Studer procedure) was achieved. R0 resection was performed in 11 (78.5 %) cases, the presence of microscopic tumor growth in the lateral resection margin was found in 3 (21.5 %)  patients (R1). Postoperative complications occurred in 8 patients, requiring surgical correction in 3 cases. Long-term results were followed up in 12 patients during the period from 16 to 57 months after surgery (median — 31 months). Overall survival in these periods was  83.3 % (10 patients). Disease-free survival — 75 % (9 patients). Influence of the reconstruction phase on the long-term results was not observed. Functional results are evaluated as good in all patients after orthotopic plastic of the bladder. Performing of pelvic exenteration for patients with locally advanced rectal cancer is a chance to achieve radical removal of the tumor and, as a consequence, the long-term survival in this extremely difficult group of patients. Performing of full reconstruction of the urinary tract allows to improve the quality of life of patientswith no adverse influence on oncologic outcomes.

1. Heald R.J. A new approach to rectal cancer. Br J Hosp Med 1979 Sep;22(3):277−81.

2. Fisher B., Wolmark N., Rockette H., Redmond C., Deutsch M., Wickerham D.L.,

3. Fisher E.R., Caplan R., Jones J., Lerner H. et al. Postoperative adjuvant chemotherapy or

4. radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988 Mar 2;80(1):21−9.

5. Gйrard A., Buyse M., Nordlinger B., Loygue J., Pиne F., Kempf P., Bosset J.F., Gignoux M., Arnaud J.P., Desaive C. et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment

6. of Cancer (EORTC).

7. Pеhlman L., Glimelius B. Local recurrences after surgical treatment for rectal carcinoma. Acta Chir Scand 1984;150(4):331−5.

8. Федоров В.Д., Воробьев Г.И., Ривкин В.Л. Клиническая оперативная колопроктология. М., 1994.

9. Krivokapic Z., Barisic G., Markovic V., Popovic M., Antic S., Jovanovic D., Protic S. First thousand rectal cancer cases — local recurrence and survival. Acta Chir Iugosl 2004;51(2):133−7.

10. Mahteme H., Pеhlman L. Good colorectal cancer surgery. Tech Coloproctol 2005 Apr;9(1):1−7.

11. Rahbari N.N., Ulrich A.B., Bruckner T., Mьnter M., Nickles A., Contin P., Lцffler T.,

12. Reissfelder C., Koch M., Bьchler M.W., Weitz J. Surgery for locally recurrent rectal

13. cancer in the era of total mesorectal excision: is there still a chance for cure? Ann Surg 2011 Mar;253(3):522−33.

14. Den Dulk M., Marijnen C.A., Putter H., Rutten H.J., Beets G.L., Wiggers T., Nagtegaal I.D., van de Velde C.J. Risk factors for adverse outcome in patients with rectal cancer treated with an

15. abdominoperineal resection in the total mesorectal excision trial. Ann Surg 2007 Jul;246(1):83−90.

16. Nagtegaal I.D., Quirke P. What is the role for the circumferential margin in the modern

17. treatment of rectal cancer? J Clin Oncol 2008 Jan 10;26(2):303−12.

18. Solomon M., Austin K., Lee P., Holm T., Rasmussen P.C. Treatment of local recurrence of rectal cancer. Ugeskr Laeger 2011 Apr 4;173(14):1047−9.

19. Lindsetmo R.O., Joh Y.G., Delaney C.P. Surgical treatment for rectal cancer: An international perspective on what the medical gastroenterologist needs to know.World J Gastroenterol 2008 June 7; 14(21):3281−9.

20. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2005 г. М., 2007.

21. Secco G.B., Fardelli R., Rovida S., Gianquinto D., Baldi E., Bonfante P., Derchi L., Ferraris R. Is intensive follow-up really able to improve prognosis of patients with local recurrence after curative surgery for rectal cancer? Ann Surg Oncol 2000 Jan−Feb;7(1):32−7.

22. Brunschwig A. Complete excision of pelvic viscera for advanced carcinoma cancer; a one-stage abdominperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy. Cancer 1948;1(2):177−83.

23. Brunschwig A. Complete excision of pelvic viscera in the male for advanced carcinoma

24. of the sigmoid invading the urinary bladder. Ann Surg 1949;129(4):499−504.

25. Brunschwig A., Daniel W. Pelvic exenteration operations: With summary of 66 cases surviving more then 5 years. Ann Surg 1960;151:571−6.

26. Brunschwig A., Daniel W. Total and anterior pelvic exenteration. Report of

27. results based upon 315 operations. Surg Gynecol Obstet 1954 Sep;99(3):324−30.

28. Широкопад В.И. Хирургическое лечение местно-распространенных опухолей органов малого таза. Меди цина, 2008.

29. Russo P., Ravindran B., Katz J., Paty P., Guillem J., Cohen A.M. Urinary diversion

30. after total pelvic exenteration for rectal cancer. Ann Surg Oncol 1999 Dec;

31. (8):732−8.

32. Ferenschild F.T.J., Vermaas M., Verhoef C., Ansink A.C., Kirkels W.J., Eggermont A.M.M., de Wilt J.H.W. Total pelvic exenteration for primary and recurrent malignancies. World J Surg 2009 July;33(7):1502−8.

33. Ali A.T., Clagett G.P., Edwards M.J. Complex venous and arterial reconstruction

34. with deep vein after pelvic exenterative surgery: a case report. Am Surg 2006 Jan; 72(1):22−4.

35. Белов Ю.В., Скипенко О.Г., Завенян З.С., Макеев Ю.М., Троицкий А.А., Тулина И.А., Царьков П.В. Резекция и протезирование абдоминального отдела аорты при удалении метастаза рака сигмовидной кишки в парааортальные лимфатические узлы. Хирургия. Журнал им. Н.И. Пирогова. 2007;3:54−7.

36. Kido A., Koyama F., Akahane M., Koizumi M., Honoki K., Nakajima Y., Tanaka Y. Extent and contraindications for sacral amputation in patients with recurrent rectal cancer: a systematic literature review. J Orthop Sci 2011 May;16(3):286−90.

37. Melton G.B., Paty P.B., Boland P.J., Healey J.H., Savatta S.G., Casas-Ganem J.E., Guillem J.G., Weiser M.R., Cohen A.M., Minsky B.D., Wong W.D., Temple L.K. Sacral resection

38. for recurrent rectal cancer: analysis of morbidity and treatment results. Dis Colon Rectum 2006 Aug;49(8):1099−107.

39. Pruthi R.S., Stefaniak H., Hubbard J.S., Wallen E.M. Robot-assisted laparoscopic anterior pelvic exenteration for bladder cancer in the female patient. J Endourol 2008 ct;22(10):2397−402;discussion 2402.

40. Skrovina M., Stursa M., Czudek S., Bartos J., Soumarovб R., Adamcнk L. Laparoscopy-assisted exenteration of the pelvis in a locally advanced rectal carcinoma. Rozhl Chir 2006 Mar;85(3):129−33.

41. Puntambekar S., Kudchadkar R.J., Gurjar A.M., Sathe R.M., Chaudhari Y.C., Agarwal G.A., Rayate N.V. Laparoscopic pelvic exenteration for advanced pelvic cancers: a review of 16 cases. Gynecol Oncol 2006 Sep;102(3):513−6.

42. De Wever I. Pelvic exenteration: surgical aspects and analysis of early and late

43. morbidity in a series of 106 patients. Acta Chir Belg 2011 Sep−Oct;111(5):273−81.

44. Kyriazi M.A., Stafyla V.K., Kondi-Pafiti A., Arkadopoulos N., Dafnios N., Hasiakos D., Fotiou S., Mastorakos D., Smyrniotis V. A novel technique for surgical reconstruction of the

45. perineal floor following anteroposterior exenteration of the pelvis — case report and

46. review of the literature. Eur J Gynaecol Oncol 2010;31(2):201−5.

47. Stechl N.M., Baumeister S., Grimm K., Kraus T.W., Bockhorn H., Exner K.E.

48. Microsurgical reconstruction of the pelvic floor after pelvic exenteration. Reduced

49. morbidity and improved quality of life by an interdisciplinary concept. Chirurg

50. Jul;82(7):625−30.

51. Ikenaga M., Miyazaki M., Yasui M., Mishima H., Tsujie M., Miyamoto A., Hirao M., Fujitani K., Nakamori S., Yoshitatsu S., Tsujinaka T. A case of total pelvic exenteration and reconstruction of perianal skin defect using a VY advancement of bilateral gluteus maximus musculocutaneous flaps for anal canal cancer associated with anal fistula. Gan To Kagaku Ryoho 2010 Nov;37(12):2650−2.

52. Gannon C.J., Zager J.S., Chang G.J., Feig B.W., Wood C.G., Skibber J.M., Rodriguez-Bigas M.A. Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma. Ann Surg Oncol 2007 Jun;14(6):1870−7.

53. Nielsen M., Rasmussen P., Lindegaard J., Laurberg S. A 10-year experience of total pelvic exenteration for primary advanced and locally recurrent rectal cancer based on a prospective database. Colorectal Dis 2011 Nov 22.

54. Jiang Y., Wan Y.L., Liu Y.C., Wang X., Pan Y.S., Wu T., Wang P.Y., Huang S.J. Surgical outcomes for 187 patients with locally recurrent rectal cancer and analysis of prognostic factors. Zhonghua Wei Chang Wai Ke Za Zhi 2011 Aug;14(8):582−5.

55. Wydra D., Emerich J., Sawicki S., Ciach K., Marciniak A. Major complications following exenteration in cases of pelvic malignancy: a 10-year experience. World J Gastroenterol 2006 Feb 21;12(7):1115−9.

56. Moriya Y., Akasu T., Fujita S., Yamamoto S. Total pelvic exenteration with distal sacrectomy for fixed recurrent rectal cancer in the pelvis. Dis Colon Rectum 2004 Dec;47(12):2047−53; discussion 2053−4.

57. Ike H., Shimada H., Ohki S., Yamaguchi S., Ichikawa Y., Fujii S. Outcome of total pelvic exenteration for locally recurrent rectal cancer. Hepatogastroenterology 2003 May−Jun;

58. (51):700−3.

59. Ishiguro S., Akasu T., Fujita S., Yamamoto S., Kusters M., Moriya Y. Pelvic exenteration for clinical T4 rectal cancer: oncologic outcome in 93 patients at a single institution over a 30-year period. Surgery 2009 Feb;145(2):189−95.

60. Ike H., Shimada H., Yamaguchi S., Ichikawa Y., Fujii S., Ohki S. Outcome of total pelvic exenteration for primary rectal cancer. Dis Colon Rectum 2003 Apr; 46(4):474−80.

61. Vermaas M., Ferenschild F.T., Verhoef C., Nuyttens J.J., Marinelli A.W., Wiggers T., Kirkels W.J., Eggermont A.M., de Wilt J.H. Total pelvic exenteration for primary locally advanced and locally recurrent rectal cancer. Eur J Surg Oncol 2007 May;33(4):452−8.

62. Peeters K.C., Marijnen C.A., Nagtegaal I.D., Kranenbarg E.K., Putter H., Wiggers T., Rutten H., Pahlman L., Glimelius B., Leer J.W., van de Velde C.J. Dutch Colorectal Cancer Group. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007 Nov;

63. (5):693−701.

64. Roh M.S., Yothers G.A., O'Connell M.J., Beart R.W., Pitot H.C. et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 2011; 29(suppl):Abst 3503.

65. Yoneda A., Okada K., Matsuo M., Kajiyama M., Kishikawa H. Four cases of locally advanced colorectal cancer resected successfully after preoperative chemotherapy. Gan To Kagaku Ryoho 2011 Oct;38(10): 1699−703.

66. Lim S.B., Choi H.S., Jeong S.Y., Kim D.Y., Jung K.H., Hong Y.S., Chang H.J., Park J.G.

67. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers. Ann Surg 2008 Aug;248(2):243−51.

68. Scutari F., Tramutola G., Morlino A., Rossi M.T., Manzione L., Rosati G., Sopranzi A. Downstaging after neoadjuvant therapy for rectal cancer modifies the planned original surgery. G Chir 2008 Jun−Jul;29(6−7):277−80.